Best Lentiviral Vector CDMOs in United Kingdom

· updated as new inspection, certificate, and trial data enters the platform
← All Lentiviral CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China
12
CDMOs tracked
10
Fully scored
4
With FDA records
21
FDA inspections
48
EMA/MHRA GMP certs

Lentiviral vectors are the workhorse of ex vivo gene therapy — used to engineer T cells for CAR-T, TCR programs, and to modify hematopoietic stem cells for inherited disorders. Because the vector integrates into the genome of patient-bound cells, lentiviral manufacturing carries the regulatory weight of a critical starting material under full GMP, mandatory replication-competent lentivirus (RCL) testing, and BSL-2 containment throughout production.

Selecting a lentiviral vector CDMO comes down to five buyer-critical dimensions: BSL-2 containment maturity and site inspection history on lentivirus specifically, a scalable suspension (or well-run adherent) platform, qualified titer + potency + RCL assays, capacity headroom at your target dose × patient volume, and defensible tech-transfer support. The rankings below score each CDMO on FDA inspection classifications, EMA/MHRA GMP density, ClinicalTrials.gov sponsor breadth, and monitored capacity signals — a composite that reflects the regulatory record and operational depth needed for material that lands in patient-bound cells.

FDA inspection outcomes across these CDMOs: 11 NAI (no action), 10 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (32), United States (18), France (7), Ireland (4), Germany (3).

Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
 83.1 97.9 6 insp · 10 GMP Available 2 programs
2
OX
Oxford Biomedica
Oxford, United Kingdom
 77.1 100.0 0 insp · 13 GMP Available 7 programs
3
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
 91.7 98.7 8 insp · 11 GMP Limited 0 programs
4
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
 88.0 100.0 0 insp · 3 GMP — 0 programs
5
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
 86.9 100.0 3 insp · 0 GMP Available 0 programs
6
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
 81.0 98.8 4 insp · 8 GMP — 0 programs
7
AA
Ascend Advanced Therapies
London, United Kingdom
 78.1 100.0 0 insp · 1 GMP — 0 programs
8
AD
Advent Bioservices
London, United Kingdom
 78.1 100.0 0 insp · 2 GMP — 0 programs
9
VB
VintaBio
Cambridge, MA
 59.0 — — — 0 programs
10
VM
Vector BioMed
Cambridge, MA
 59.0 — — — 0 programs
—
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
 Profiled — — — 0 programs
—
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
 Profiled — — — 0 programs
How we score CDMOs →

What to evaluate in a Lentiviral Vector CDMO

Containment & biosafety
Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.
Process platform maturity
Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.
Analytics & potency
Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.

How has post-Brexit MHRA / EMA divergence affected UK CDMO selection?

Since 1 January 2021 the UK has operated MHRA as an independent regulator distinct from EMA. Practically this means: (1) UK manufacturing for EU-market supply requires a separate EMA GMP certificate, held by an EU-based Qualified Person; (2) EU manufacturing for UK-market supply requires MHRA acceptance, though MHRA has continued to recognize EMA GMP inspections under transitional arrangements; (3) the batches themselves may need to be released twice (once by an EU QP for EU supply, once by a UK QP for UK supply). CDMOs with UK + EU footprints are increasingly common in response; UK-only CDMOs need to arrange separate EU QP release for European supply. The Signal Score's Quality Compliance pillar captures both MHRA and EMA GMP certificates, so dual-jurisdiction CDMOs typically rank higher on this pillar.

Which UK CDMOs also cover FDA (US) regulatory geography?

UK CDMOs with US FDA inspection history qualify to supply US-market programs; those without FDA posture are limited to UK + EU. British CDMOs with FDA inspection density typically rank higher on the Signal Score's Quality Compliance pillar because that pillar aggregates FDA + EMA + MHRA data directly. Cross-check with the US region ranking — CDMOs appearing on both UK and US rankings have demonstrated multi-jurisdictional inspection posture, which materially reduces regulatory tech-transfer risk for programs supplying both markets.

How CDMO Signal identifies UK manufacturing presence

UK region attribution derives from each CDMO's declared facility locations. A location string containing UK-specific tokens (England, Scotland, Wales, Northern Ireland, London, Oxford, Cambridge, Liverpool, Manchester, Edinburgh, or 'UK'/'United Kingdom') places the CDMO in the UK region. Multi-site CDMOs appear in every applicable region — a Cambridge + Basel + Boston CDMO shows on UK, Europe, Switzerland, and USA rankings. Sponsors evaluating for a specific program should verify facility-level detail on the individual CDMO profile page — a CDMO with UK presence may only run some processes there and route others through their non-UK sites.

Lentiviral Vector CDMOs — Frequently Asked Questions

Who are the top Lentiviral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include Thermo Fisher Scientific, Oxford Biomedica, Charles River Laboratories. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Lentiviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 4 Lentiviral Vector CDMOs with FDA inspection records and 48 EMA/MHRA GMP certificates across the group.
What should I look for in a lentiviral vector CDMO?
Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.
How is lentiviral vector manufacturing different from AAV?
Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.
Related modalities
Cell Therapy CDMOs CAR-T CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector